Clinical Genetics · Orange, CA
NPI
1912964925
Since 2006
Specialty
Clinical Genetics
Code 207SG0201X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
101 the City Dr S # Zc4482, Division of Genetics and Metabolism
Orange, CA, 92868
Phone (714) 456-5792
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$2.0M
126 prescriptions
Company payments, 2025
$15K
From 5 companies
Medicare prescription drug claims, 2024
In 2024, the drug Virginia E Kimonis prescribed most often to Medicare patients was Fabrazyme (Agalsidase Beta), with 66 prescriptions and refills. In total Virginia E Kimonis wrote 126 Medicare prescriptions that cost $2.0M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-02-28.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Fabrazyme Agalsidase Beta | 66 | 66 | Under 11 | $956K |
| Lumizyme Alglucosidase Alfa | 27 | 27 | Under 11 | $1.0M |
| Sodium Chloride 0.9 % Sodium Chloride | 27 | 27 | Under 11 | $215 |
Brand drugs: 122 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Virginia E Kimonis $15K ($15K in general payments such as food, travel and fees) from 5 companies. The largest payer was Genzyme Corporation with $9,815.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.